NCCN Guidelines® Insights - Head and Neck Cancers, Version 1.2022
The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses. Occult primary cancer, salivary gland cancer, and mucosal melanoma (MM) are also addressed. The speciﬁc site of disease, stage, and pathologic ﬁndings guide treatment (eg, the appropriate surgical procedure, radiation targets, dose and fractionation of radiation, indications for systemic therapy). The NCCN Head and Neck Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding management of HPV-positive oropharynx cancer and ongoing research in this area.
This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for Head and Neck Cancers
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Head and Neck Cancers
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Individuals Who Provided Content Development and/or Authorship Assistance
The faculty listed below have no relevant financial relationships with ineligible companies to disclose.
Sharon Spencer, MD, Panel Vice Chair
Ellie Maghami, MD, Panel Member
Jennifer L. Burns, BS, Manager, Guidelines Support, NCCN
Susan D. Darlow, PhD, Oncology Scientist/Senior Medical Writer, NCCN
The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
David Pfister, MD, Panel Chair, grant/research support from Bristol-Myers Squibb Company, Genentech, Inc., Cue Biopharma, Hookipa Pharma Inc., Kura Oncology, Inc., Merck & Co., Inc., and Novartis Pharmaceuticals Corporation; and data safety monitoring committee member for Boehringer-Ingelheim, GmbH.
Douglas Adkins, MD, Panel Member, grant/research support from AstraZeneca Pharmaceuticals LP, BeiGene, Blueprint Medicines, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eisai Inc., Eli Lilly and Company, Exelixis Inc., Gilead Sciences, Inc., Hookipa Pharma Inc., Kura Oncology, Inc., Merck & Co., Inc., Adlai-Nortye, CUE Biosciences, Debio, Epizme, Isa Therapeutics, Oncolys, Rubius, Vaccinex, Pfizer Inc., and Roche Laboratories, Inc.; and consulting fees from Blueprint Medicines, Boehringer Ingelheim GmbH, Eisai Inc., Exelixis Inc., Kura Oncology, Inc., Merck & Co., Inc., Coherus Biosciences, CUE Biosciences, Immunitas, Targimmune, Vaccinex, and Xilio.
David M. Brizel, MD, Panel Member, royalty income from UpToDate.
Jimmy J. Caudell, MD, PhD, Panel Member, grant/research support from Varian Medical Systems, Inc.; and scientific advisor for Galera.
A. Dimitrios Colevas, MD, Panel Member, grant/research support from AbbVie, Inc., Atara Biotherapeutics, BioNTech, Cue, Cullinan Oncology, Exelixis, Inc., Gilead Sciences, Inc., Innate Pharma, Replimune Group, and Tessa Therapeutics; consulting fees from Grand Rounds and PDS Biotech; and scientific advisor for Gilead Sciences, Inc.
Maura L. Gillison, MD, PhD, Panel Member, grant/research support from Bristol-Myers Squibb Company, Gilead Sciences, Inc., and Kura Oncology, Inc.; and consulting fees from Bayer HealthCare, Bristol-Myers Squibb Company, Eisai Inc., EMD Serono, Ipsen, Merck & Co., Inc., Nektar Therapeutics, and Roche Laboratories, Inc.
Cristina P. Rodriguez, MD, Panel Member, grant/research support from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Kura Oncology, Inc., Merck & Co., Inc., Ayala, and Cue; and scientific advisor for Coherus and Cue.
David Sher, MD, MPH, Panel Member, grant/research support from Varian Medical Systems, Inc.
Gregory Weinstein, MD, Panel Member, royalty income from Olympus Corporation.
Francis Worden, MD, Panel Member, honoraria from Bayer HealthCare; and scientific advisor for Eisai Inc., Exelixis Inc., Merck & Co., Inc.
View all of the conflicts of interest for the NCCN Guidelines panel
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-22-003-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until March 10, 2023. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
To access this activity, users will need:
- A device with an Internet connection
- Adobe Reader or other PDF reader software for article and certificate viewing/printing